The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
about
Virulence factors of medically important fungiAntibodies Raised Against Chlamydial Lipopolysaccharide Antigens Reveal Convergence in Germline Gene Usage and Differential Epitope RecognitionRemarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemiaMelanization of Cryptococcus neoformans in murine infection.Cas3p belongs to a seven-member family of capsule structure designer proteins.UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 degrees C and for capsule biosynthesisMouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformansOrgan-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infectionThe different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceMurine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccineCryptococcus neoformans induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta in human microglia: role of specific antibody and soluble capsular polysaccharide.The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Fcgamma receptor I- and III-mediated macrophage inflammatory protein 1alpha induction in primary human and murine microgliaAntibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigenPathogenesis of pulmonary Cryptococcus neoformans infection in the ratAntibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodiesProduction of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.Distinct and redundant roles of exonucleases in Cryptococcus neoformans: implications for virulence and mating.Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophagesAnalysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Mouse variable-region gene families: complexity, polymorphism and use in non-autoimmune responses.Limiting CDR-H3 diversity abrogates the antibody response to the bacterial polysaccharide α 1→3 dextran.Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro.Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naïve and memory B cells.Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infectionMolecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cellImmunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclassesMolecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivoProtective murine monoclonal antibodies to Cryptococcus neoformans
P2860
Q24683790-93102249-88A6-466A-8BB8-61F4B2598C16Q27658569-51E0FC65-0E3B-4144-B491-A8518F62FE18Q29048141-58041EF9-374D-473B-9167-1E6AFC6C3E92Q31951268-9AA2B520-5644-402E-937E-BF36331FB10AQ33560210-8CCFE406-E358-4041-8991-795A4D09F4ABQ33560489-81F9F966-53B3-4677-8179-21DE72B96879Q33754371-296CB8D0-8260-4352-8E4F-0EAEC6EC20E2Q33754495-9AE962AC-C8BD-45AC-B66E-9FF250010CD3Q33766953-AD86DB5D-6273-4EF1-AED8-498588C82E10Q33991158-9CE99C3D-2BA1-4FBC-B62A-7573FA87D682Q34001701-4B3C92E8-D162-40C7-B1A6-9A683135E5A3Q34003052-DA77E084-DA14-41D1-A581-3199FE97DD26Q34006498-3A84DC0B-64B3-4E86-935F-B8F45EF41521Q34099803-CA73F47C-2BF4-4D46-A25D-5A39D1C507A1Q34130404-BF56760A-D355-490E-B458-F1498992F11AQ34146715-336AEE58-39D4-42B7-829F-3429D0854D00Q34543565-88E49D38-34ED-478C-8C66-06E88A2CF21FQ34757345-2BF91F62-D6B2-4099-BFB3-4716AE8C212DQ35225603-97EEE08F-75C5-474E-B567-BA2B667B58EAQ35240882-F224DB4D-E6AD-461D-977E-ED452344D91EQ35386000-B0331B53-1F4B-46B6-9FD7-ECB7AE823CE1Q35428887-B43ABFAA-87AA-4CA4-871D-FF8A71416645Q35434901-EDFB8F0F-0F39-4945-82CA-BAD16E69DB4BQ35499819-ABCA6D61-50F2-473D-8C8E-DD5D81EDC7C3Q35533445-FFF621F1-5872-45FD-AF7C-BC66FD77961BQ35547271-10A889B8-F4F3-4469-A688-75A09FDFBD4BQ35567548-5F55777A-4EA7-4C33-B89B-24EFEC85727CQ35768284-C74C9C9F-067E-4A60-AD4E-E5F4016D5709Q35773483-DDFF42DE-902A-4F56-B862-7AD49B6C6BA1Q35775466-E98A0CBD-B139-4ABD-ADAB-2E877C8F096FQ36047782-A0E3F49B-2083-484F-876D-24DAFF8E05B9Q36255421-6F73ED23-A2A6-47EE-A007-30B36D94E3E1Q36361541-3CD1228D-4DC3-4676-832D-22A61623EC15Q36364342-E598BE7E-1917-4E41-AD23-B4599058102FQ36366474-B1265886-5F54-4CC8-82C1-390F79113ECEQ36376827-518886C1-FCBA-4055-8675-961C7016AE98Q36400281-72703AD0-2441-4063-8460-8D2215925746Q36456615-DF454E61-3416-4EF3-A980-43F64F40C3FCQ36649929-2D3BCD87-3B5D-4BDA-BE0A-36BC3205F457Q36969771-58D50F04-D099-4C94-8893-FC015A4468AC
P2860
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
The mouse antibody response to ...... saccharide binding antibodies.
@ast
The mouse antibody response to ...... saccharide binding antibodies.
@en
type
label
The mouse antibody response to ...... saccharide binding antibodies.
@ast
The mouse antibody response to ...... saccharide binding antibodies.
@en
prefLabel
The mouse antibody response to ...... saccharide binding antibodies.
@ast
The mouse antibody response to ...... saccharide binding antibodies.
@en
P2860
P356
P1476
The mouse antibody response to ...... saccharide binding antibodies.
@en
P2093
A Casadevall
M D Scharff
P2860
P304
P356
10.1084/JEM.174.1.151
P407
P577
1991-07-01T00:00:00Z